- Home
- REFI vs SGHT Comparison
REFI vs SGHT Comparison
Compare REFI & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- SGHT
- Stock Information
- Founded
- REFI 2021
- SGHT 2011
- Country
- REFI United States
- SGHT United States
- Employees
- REFI N/A
- SGHT N/A
- Industry
- REFI Real Estate Investment Trusts
- SGHT Medical Specialities
- Sector
- REFI Real Estate
- SGHT Health Care
- Exchange
- REFI Nasdaq
- SGHT Nasdaq
- Market Cap
- REFI 306.1M
- SGHT 304.4M
- IPO Year
- REFI 2021
- SGHT 2021
- Fundamental
- Price
- REFI $16.18
- SGHT $3.57
- Analyst Decision
- REFI Strong Buy
- SGHT Buy
- Analyst Count
- REFI 3
- SGHT 7
- Target Price
- REFI $20.00
- SGHT $6.27
- AVG Volume (30 Days)
- REFI 118.5K
- SGHT 218.9K
- Earning Date
- REFI 11-07-2024
- SGHT 11-07-2024
- Dividend Yield
- REFI 11.63%
- SGHT N/A
- EPS Growth
- REFI N/A
- SGHT N/A
- EPS
- REFI 2.00
- SGHT N/A
- Revenue
- REFI $56,860,278.00
- SGHT $79,543,000.00
- Revenue This Year
- REFI N/A
- SGHT $2.13
- Revenue Next Year
- REFI $4.27
- SGHT $7.99
- P/E Ratio
- REFI $8.08
- SGHT N/A
- Revenue Growth
- REFI 6.49
- SGHT N/A
- 52 Week Low
- REFI $14.82
- SGHT $3.30
- 52 Week High
- REFI $17.65
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- REFI 56.28
- SGHT 39.52
- Support Level
- REFI $15.69
- SGHT $3.45
- Resistance Level
- REFI $16.24
- SGHT $3.64
- Average True Range (ATR)
- REFI 0.20
- SGHT 0.19
- MACD
- REFI -0.02
- SGHT 0.03
- Stochastic Oscillator
- REFI 79.03
- SGHT 31.90
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.